Preface
Renal Hemodynamic Effects of Beta-Blockers in Hypertension
Hemodynamic Effects of Beta-Blockade in Hypertension. A Critical Review
Safar, M.E
Renal Blood Flow in Man with Essential Hypertension
London, G.M.; Safar, M.E.; Marchais, S
Acute Renal Effects of Beta-Blockers
Renal Hemodynamic Effects of Tertatolol Compared with Those of Propranolol in the Conscious Dog
Laubie, M.; Prost, J.-F.; Rochat, C
Role of Baroreflex Activation in the Regional Hemodynamic Effects of the Beta-Blockers Tertatolol and Propranolol in Conscious Spontaneously Hypertensive Rats
Struyker-Boudier, H.A.J.; van Essen, H.; Nievelstein, H.M.N.W.; Smits, J.F.M
Study of Prejunctional Beta-Adrenoceptors in Kidneys of Normotensive and Hypertensive Rats Using the New Beta-Adrenoceptor Blocking Drug Tertatolol
Verbeuren, T.J.; Herman, A.G
Tertatolol Preserves Renal Perfusion in Patients with Arterial Hypertension after Head Injury
Leeman, M.; Naeije, R.; Degaute, J.-P.; Brackman, F.; Thomas, J.; Prost, J.-F
Renal Hemodynamic Effects of Tertatolol in Essential Hypertension
Paillard, F.; Lantz, B.; Leveil, F.; Ardaillou, R
Antihypertensive and Renal Effects of Tertatolol, a New Beta-Blocking Agent, in Hypertensive Patients
Salvetti, A.; Leonetti, G.; Bernini, G.P.; Rupoli, L.; Lucarini, A.R.; Sangiorgio, P.; Mauro, M.; Di Stratis, P.; Zanchetti, A
Effects of Tertatolol in Hypertensive Patients with Chronic Renal Failure
Beaufils, M.; Lantz, B.; Paillard, F.; Richet, G
Time Course Assessment of Beta-Blocking Therapy in Hypertension
24-Hour Blood Pressure Measurements: Methodological and Clinical Problems Parati, G.; Pomidossi, G.; Malaspina, D.; Camesasca, C; Mancia, G.
Biodisposition of Tertatolol in Man: A Review
Campbell, D.B.; Chignon, J.C.; Devissaguet, J.Ph
Beta-Adrenergic Receptor Changes during Tertatolol Treatment in Healthy Volunteers: Relevance for Beta-Blocking Therapy
De Blasi, A.; Lipartiti, M.; Garattini, S 69
Choosing the Right Dose for Beta-Blocker Treatment of Hyper tension: Experience with Tertatolol
Prost, J.-F.; Desche, P.; Richard, Ch.; Safar, M.E 74
Antihypertensive Effects of Tertatolol: 3-Month Comparative Study against Acebutolol
Gallet, M.; Kleinknecht, D.; Maurice, P 83
Consequences of Beta-Blocking Therapy on Heart and Vessels
Effects of Beta-Adrenergic Blockade on the Arterial Vasculature in Essential Hypertension
Levenson, J.A.; Simon, A.Ch.; Zabludowski, J.E.; Safar, M.E. ... 88
Reversal of Left Ventricle Hypertrophy following Treatment with Beta-Blockers: Experience with Tertatolol
Trimarco, B.; Ricciardiello, B.; de Luca, N.; Cuocolo, A.; Volpe, M.; Lembo, G.; Condorelli, M 94
Tertatolol Does Not Affect Biochemical Markers of Atherosclerosis in Normo- and Hyperlipidemic Hypertensive Patients
Richard, J.-L.; Martin, C.; Jacotol, B 100
Long-Term Experience with Tertatolol in Hypertension
Komajda, M.; Genevray, B.; Grosqogeat, Y 106
Concluding Remarks
Zanchetti, A 113
Author Index 115
Subject Index 116 Recent Advances in Beta Blockade
Therapeutic Implications in Hypertension
Proceedings of the First International Symposium on Tertatolol 15th June, 1985, Milano, Italy
Supported by:
Institut de Recherches Internationales Servier
Guest Editors:
M.E. Safar, Paris
A. Zanchetti, Milano
S. G. Massry, Los Angeles, Calif.
57 figures and 29 tables, 1986

HUB
American Journal of Nephrology
Vol. 6, Supplement 2, 1986
S. Karger · Medical and Scientific Publishers · Basel · München · Paris · London · New York · New Delhi · Singapore · Tokyo · Sydney
Drug Dosage
The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of
publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved.
No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center (see ‘Information for Readers and Subscribers’).
© Copyright 1986 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland) Printed in Switzerland by Graphische Anstalt Schiiler AG, Biel ISBN 3-8055-4442-1